Close

Anti-CDH2 DNA-encoded mAb (DMAb), pVAX1 (DMAb-0380-CQ)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This product is the plasmid containing an encoded anti-CDH2 DMAb sequence. The plasmid can drive transcription and in vivo translation of the desired antibody.

  Add to Cart

Specifications

  • Target
  • CDH2
  • Vector Name
  • pVAX1
  • Vector Description
  • pVAX1 was originally designed for the development of DNA vaccines. Its eukaryotic DNA sequences limited to the expression of desired sequence so that minimize the possibility of chromosomal integration. This vector has been widely used for the construction of DMAb plasmid.
  • Vector Promoter
  • CMV
  • Vector Tag or Fusion
  • Untagged
  • Delivery Method
  • Transfection
  • Cloning Method
  • Restriction Enzyme ⁄ MCS
  • Constitutive or Inducible System
  • Constitutive
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term.
  • Background
  • DNA-encoded mAb (DMAb) technology is a novel approach for a direct in vivo production of desired biologically active immunoglobulins according to the plasmid DNA delivery into tissue where the delivered plasmid containing an encoded antibody sequence. Compared with the traditional mAb, DMAb can be functionally equivalent with additional advantages such as expression profiles, glycosylation, as well as no reliance on in vivo tissue culture and costly or time-consuming production systems. The DMAb technology may provide a novel, simple, less frequent, cost-effective approach for therapeutics.

Target

  • Entrez Gene ID
  • 1000
Sub CAT. DMAb Clone DMAb Host Target Species DMAb Isotype DMAb Immunogen  
DMAb-0381-CQ CDH2/1573 Mouse IgG1, κ A human partial recombinant protein corresponding to the intracellular portion of CDH2
DMAb-0358-WJ 13A9 Mouse IgG1 Cytoplasmic domain of human N Cadherin.
DMAb-0359-WJ 8C11 Mouse IgG1 Bacterial fusion protein corresponding to the extracellular domain of N-cadherin
DMAb-0363-WJ 1C5 Mouse Human IgG1 The extracellular domain of human CDH2 (NP_001783) produced in human cells
DMAb-0364-WJ 2G7 Mouse IgG2a
DMAb-0366-WJ 3B9 Mouse IgG1, κ Recombinant domain corresponding to the intracellular domain of chicken N-Cadherin
DMAb-0367-WJ 3G48 Rat IgG2a Neuronal tissue of chick embryos
DMAb-0368-WJ 5D5 Mouse IgG1 Purified recombinant fragment of human CDH2 expressed in E. Coli
DMAb-0370-WJ D4R1H Rabbit Human
DMAb-0371-WJ FA-5 Mouse Chicken IgG1
DMAb-0372-WJ GC-4 Mouse IgG1 Recombinant full length protein (Chicken heart)
DMAb-0373-WJ M170 Mouse IgG1
DMAb-0375-WJ NCD-2 Rat IgG2a Neuronal tissue of chick embryos

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CDH2 DNA-encoded mAb (DMAb), pVAX1 (DMAb-0380-CQ). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.